UNSPSC 51286001: Dichlorophenarsine

This classification denotes an anti-infective agent with the molecular formula C6H6AsCl2NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3WD5400T9N, chemically known as phenol, 2-amino-4- (dichloroarsino)-, hydrochloride but more generally known as dichlorophenarsine, which bears US NIH Compound Identifier 68302. European Medicines Agency schedules Dichlorophenarsine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07086MIG. The term DICHLOROPHENARSINE is an International Non-Proprietary Name.

DICHLOROPHENARSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [AS](CL)(CL)C1CC(N)C(O)CC1.

UNSPSC 51286001 Dichlorophenarsine is a Commodity code that does not reflect the work state and local governments are actually procuring under this classification. Recent solicitations tagged to this code cover pharmaceutical procurement, emergency medical supplies, and pharmacy benefit management programs — none of which align with dichlorophenarsine, an arsenic-based chemical compound used in legacy industrial or laboratory applications. The mismatch suggests either a cataloging error in the state and local procurement systems that tagged these opportunities or a fundamental misalignment between the code's nominal scope and current buying activity. The code shows little relevant recent activity within state and local procurement.

The opportunities posted under this code include Seminole County, Florida's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023), the City of Tampa's invitation to bid for medical and first aid supplies for the Fire Department Rescue Division (due March 13, 2026, estimated value $700,000 with an SLBE set-aside and 5% discount), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer pharmacy programs (response deadline April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products distributed through participating wholesalers (proposals due March 26, 2026). None of these procurements involve dichlorophenarsine or related arsenical compounds. Firms pursuing state and local opportunities in pharmaceutical supply, emergency medical equipment, or pharmacy benefit programs should verify the correct UNSPSC coding rather than relying on this classification.